Obesity, metabolism & miscellaneous endocrinology
Antonio Montero-Hidalgo 1 , Antonio J. Montero-Hidalgo 2 , Vicente Herrero-Aguayo 2 , Ana de la Salud De la Rosa-Herencia 2 , Enrique Gómez-Gómez 3 , Ipek Guler 4 , Justo P. Castaño 2 , André Sarmento-Cabral 2 , Manuel D. Gahete 2 , Raúl M. Luque 2 & Juan M. Jiménez-Vacas 2
1University of Cordoba/Maimonides Biomedical Research Institute of Cordoba; [email protected]; 2Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain; Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain; 3Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain; Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain; CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain; Urology Service, HURS/IMIBIC, 14004 Cordoba, Spain; 4Leuven Biostatistics and Statistical Bioinformatics Centre (L-BioStat), Katholiek Universiteit (KU) Leuven, University of Leuven, Leuven, Belgium
Background: Prostate cancer (PCa) diagnosis is based on the serum levels of prostatic specific antigen (PSA), which might be influenced by many clinical conditions, including obesity. In addition, the diagnostic capability of PSA test dramatically drops when considering patients with PSA levels lower than 10ng/mL (i.e. “grey-zone”). Therefore, the identification of more reliable non-invasive diagnostic biomarkers for PCa is a critical unmet clinical need. In this scenario, the potential diagnostic capacity of urine In1-ghrelin, a splicing variant derived from ghrelin gene with an oncogenic role in PCa, has not been explored yet, neither its potential relation with adverse metabolic conditions.
Objectives: To assess the putative relation of urine In1-ghrelin levels with metabolic-related pathological conditions (e.g. obesity, diabetes, BMI, insulin or glucose levels), and to define its potential clinical value for PCa patients with PSA in the grey-zone.
Methods: Urine In1-ghrelin levels were determined by RIA in a metabolically well-characterized cohort of patients with PSA in the grey-zone (n=600).
Results: In1-ghrelin levels were strongly correlated with those of key obesity-related parameters, including BMI, diabetes, glucose and insulin among others. Moreover, high In1-ghrelin levels were associated with increased PCa-risk and linked to PCa aggressiveness parameters (e.g. tumor stage and perineural invasion). Remarkably, a multivariate model consisting of key clinical and metabolic variables, including In1-ghrelin levels, showed high specificity/sensitivity to diagnose PCa (AUC=0.740).
Conclusion: Our results indicate the association of urine In1-ghrelin levels with obesity-related factors and PCa-risk/aggressiveness. Additionally, this study poses the potential for urine In1-ghrelin levels as a useful clinical diagnostic/prognostic biomarker of PCa in patients with PSA in the grey-zone.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more